An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in participants with Body Dysmorphic Disorder.

• Conditions: Body Dysmorphic Disorder; Mental Health - Anxiety

• Registration Number: ACTRN12614000991617
• Lead Sponsor: Prof Susan Rossell

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-09-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

For Healthy controls: Right-handed; between the ages of 18-65 years; non-smoker and no drug/alcohol abuse; medication free; no neurological disorders, and no metal objects present in body (or which can't be removed or which is not MRI safe). Women who have not experienced menopause.
For Body Dysmorphic Disorder (BDD): As above plus a diagnosis of the disorder is required.

Exclusion Criteria

Clinically significant medical or neurological condition (other than BDD for the patients), significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional MRI (fMRI) data will be collected in response to an emotional face expression task. The fMRI data will be compared within the patient (Body Dysmorphic Disorder) group for differences in brain response (e.g., in the amygdala) between placebo and oxytocin conditions.[The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.]

Secondary Outcome Measures

Name	Time	Method
sing the fMRI data, the patients with BDD will be compared to healthy controls on brain response (e.g., amygdala) under normal (placebo) conditions to see whether any differences in brain activity is present.<br><br>Using the DTI and structural MRI data, the whole-brain and white matter structure of the brains of patients with BDD will be examined in comparison to the healthy control group to see if any structural or white matter differences are present.[The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.]